Intersouth Partners

CallMiner is a provider of speech and voice analytics technology that helps organizations extract insights from customer interactions, with a cloud-based platform that analyzes conversations across calls, chats, emails, SMS, surveys, and social channels. The software uses artificial intelligence and natural language processing to transcribe and interpret spoken interactions, enabling improvements in customer service, compliance monitoring, and workforce performance. The Eureka platform supports conversational analytics, automated quality monitoring, and performance management, with tools such as Eureka Live for real-time call monitoring and myEureka for feedback workflows. The solution is offered as Software-as-a-Service and on-premises installations, and supports services including training, certification, and implementation support. CallMiner serves industries including financial services, utilities, manufacturing, government, and travel, helping turn interaction data into business intelligence.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.

CallMiner is a provider of speech and voice analytics technology that helps organizations extract insights from customer interactions, with a cloud-based platform that analyzes conversations across calls, chats, emails, SMS, surveys, and social channels. The software uses artificial intelligence and natural language processing to transcribe and interpret spoken interactions, enabling improvements in customer service, compliance monitoring, and workforce performance. The Eureka platform supports conversational analytics, automated quality monitoring, and performance management, with tools such as Eureka Live for real-time call monitoring and myEureka for feedback workflows. The solution is offered as Software-as-a-Service and on-premises installations, and supports services including training, certification, and implementation support. CallMiner serves industries including financial services, utilities, manufacturing, government, and travel, helping turn interaction data into business intelligence.

CallMiner is a provider of speech and voice analytics technology that helps organizations extract insights from customer interactions, with a cloud-based platform that analyzes conversations across calls, chats, emails, SMS, surveys, and social channels. The software uses artificial intelligence and natural language processing to transcribe and interpret spoken interactions, enabling improvements in customer service, compliance monitoring, and workforce performance. The Eureka platform supports conversational analytics, automated quality monitoring, and performance management, with tools such as Eureka Live for real-time call monitoring and myEureka for feedback workflows. The solution is offered as Software-as-a-Service and on-premises installations, and supports services including training, certification, and implementation support. CallMiner serves industries including financial services, utilities, manufacturing, government, and travel, helping turn interaction data into business intelligence.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.

NovaMin Technology provides a range of oral hygiene solutions. The company was founded by Randy Scott in 2004 and is based in Alachua, Florida.

CallMiner is a provider of speech and voice analytics technology that helps organizations extract insights from customer interactions, with a cloud-based platform that analyzes conversations across calls, chats, emails, SMS, surveys, and social channels. The software uses artificial intelligence and natural language processing to transcribe and interpret spoken interactions, enabling improvements in customer service, compliance monitoring, and workforce performance. The Eureka platform supports conversational analytics, automated quality monitoring, and performance management, with tools such as Eureka Live for real-time call monitoring and myEureka for feedback workflows. The solution is offered as Software-as-a-Service and on-premises installations, and supports services including training, certification, and implementation support. CallMiner serves industries including financial services, utilities, manufacturing, government, and travel, helping turn interaction data into business intelligence.

CallMiner is a provider of speech and voice analytics technology that helps organizations extract insights from customer interactions, with a cloud-based platform that analyzes conversations across calls, chats, emails, SMS, surveys, and social channels. The software uses artificial intelligence and natural language processing to transcribe and interpret spoken interactions, enabling improvements in customer service, compliance monitoring, and workforce performance. The Eureka platform supports conversational analytics, automated quality monitoring, and performance management, with tools such as Eureka Live for real-time call monitoring and myEureka for feedback workflows. The solution is offered as Software-as-a-Service and on-premises installations, and supports services including training, certification, and implementation support. CallMiner serves industries including financial services, utilities, manufacturing, government, and travel, helping turn interaction data into business intelligence.

CallMiner is a provider of speech and voice analytics technology that helps organizations extract insights from customer interactions, with a cloud-based platform that analyzes conversations across calls, chats, emails, SMS, surveys, and social channels. The software uses artificial intelligence and natural language processing to transcribe and interpret spoken interactions, enabling improvements in customer service, compliance monitoring, and workforce performance. The Eureka platform supports conversational analytics, automated quality monitoring, and performance management, with tools such as Eureka Live for real-time call monitoring and myEureka for feedback workflows. The solution is offered as Software-as-a-Service and on-premises installations, and supports services including training, certification, and implementation support. CallMiner serves industries including financial services, utilities, manufacturing, government, and travel, helping turn interaction data into business intelligence.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.